Whether viewed as an expert or as a source of ‘knowledge hallucination’, the use of ChatGPT in medical practice has stirred ongoing debate. This study sought to evaluate ChatGPT's capabilities in the field of clinical genetics, focusing on tasks such as ‘Clinical genetics exams’, ‘Associations between genetic diseases and pathogenic genes’, and ‘Limitations and trends in clinical genetics’. Results indicated that ChatGPT performed exceptionally well in question-answering tasks, particularly in clinical genetics exams and diagnosing single-gene diseases. It also effectively outlined the current limitations and prospective trends in clinical genetics. However, ChatGPT struggled to provide comprehensive answers regarding multi-gene or epigenetic diseases, particularly with respect to genetic variations or chromosomal abnormalities. In terms of systematic summarization and inference, some randomness was evident in ChatGPT's responses. In summary, while ChatGPT possesses a foundational understanding of general knowledge in clinical genetics due to hyperparameter learning, it encounters significant challenges when delving into specialized knowledge and navigating the complexities of clinical genetics, particularly in mitigating ‘Knowledge Hallucination’. To optimize its performance and depth of expertise in clinical genetics, integration with specialized knowledge databases and knowledge graphs is imperative.

MOTIVATION: Heart failure (HF) is a cardiovascular disease with a high incidence around the world. Accumulating studies have focused on the identification of biomarkers for HF precision medicine. To understand the HF heterogeneity and provide biomarker information for the personalized diagnosis and treatment of HF, a knowledge database collecting the distributed and multiple-level biomarker information is necessary. RESULTS: In this study, the HF biomarker knowledge database (HFBD) was established by manually collecting the data and knowledge from literature in PubMed. HFBD contains 2618 records and 868 HF biomarkers (731 single and 137 combined) extracted from 1237 original articles. The biomarkers were classified into proteins, RNAs, DNAs and the others at molecular, image, cellular and physiological levels. The biomarkers were annotated with biological, clinical and article information as well as the experimental methods used for the biomarker discovery. With its user-friendly interface, this knowledge database provides a unique resource for the systematic understanding of HF heterogeneity and personalized diagnosis and treatment of HF in the era of precision medicine. AVAILABILITY AND IMPLEMENTATION: The platform is openly available at http://sysbio.org.cn/HFBD/.